Statistically conclusive or suggested result Inconclusive results Uncertain results Safety results

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
enzalutamide plus ADT vs. androgen deprivation therapy (ADT) 2 none-

suggested 34 % decrease in deaths (OS) but the degree if certainty is unassessable

-